Zhifei Biological's holding subsidiary, Chanan Biological, has completed the enrollment of the first batch of subjects for the Phase Ib clinical trial of CA111 injection.

On August 13, according to Zhifei Biological, its subsidiary, Shen'an Biological, has completed the enrollment of subjects in the first dose group of the phase Ib clinical trial for the CA111 injection on August 12. This phase Ib clinical trial aims to evaluate the safety, tolerability, pharmacokinetics, and efficacy characteristics of CA111 injection in obese/overweight subjects.